{"id":"NCT00826280","sponsor":"Astellas Pharma Inc","briefTitle":"Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)","officialTitle":"A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03-24","primaryCompletion":"2010-07-15","completion":"2010-07-15","firstPosted":"2009-01-22","resultsPosted":"2011-10-21","lastUpdate":"2024-12-03"},"enrollment":347,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Coronary Artery Disease (CAD)"],"interventions":[{"type":"DRUG","name":"regadenoson","otherNames":["Lexiscan","CVT 3146"]},{"type":"DRUG","name":"overencapsulated caffeine","otherNames":[]},{"type":"RADIATION","name":"technetium","otherNames":["sestamibi","tetrafosmin"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Placebo plus Regadenoson","type":"PLACEBO_COMPARATOR"},{"label":"Caffeine 200 mg plus Regadenoson","type":"EXPERIMENTAL"},{"label":"Caffeine 400 mg plus Regadenoson","type":"EXPERIMENTAL"}],"summary":"Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI","primaryOutcome":{"measure":"Change in Number of Reversible Defects","timeFrame":"Day 3 and Day 5","effectByArm":[{"arm":"Placebo Plus Regadenoson","deltaMin":0.67,"sd":1.377},{"arm":"Caffeine 200 mg Plus Regadenoson","deltaMin":1.01,"sd":1.452},{"arm":"Caffeine 400 mg Plus Regadenoson","deltaMin":1,"sd":1.595}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"0.9328"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":["21082298"],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=49"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":113},"commonTop":["Dyspnoea","Headache","Flushing","Chest discomfort","Dizziness"]}}